Risk of adverse events with the addition of targeted agents to endocrine therapy in patients with hormone receptor-positive metastatic breast cancer: A systematic review and meta-analysis-Reference-Cited by-同舟云学术

Risk of adverse events with the addition of targeted agents to endocrine therapy in patients with hormone receptor-positive metastatic breast cancer: A systematic review and meta-analysis

Published:2018-01 Issue: Volume:62 Page:123-132
ISSN:0305-7372
Container-title:Cancer Treatment Reviews
language:en
Short-container-title:Cancer Treatment Reviews

Author:

Martel Samuel,Bruzzone Marco,Ceppi Marcello,Maurer Christian,Ponde Noam Falbel,Ferreira Arlindo R.,Viglietti Giulia,Del Mastro Lucia,Prady Catherine,de Azambuja Evandro,Lambertini Matteo

Funder

Société des Médecins de l’Université de Sherbrooke

European Society for Medical Oncology

Publisher

Elsevier BV

Subject

Radiology Nuclear Medicine and imaging,Oncology,General Medicine

Reference38 articles.

1. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status;Howlader;J Natl Cancer Inst,2014

2. Advances in the treatment of advanced oestrogen-receptor-positive breast cancer;Turner;Lancet,2017

3. Fulvestrant 500 mg versus Anastrozole 1 mg for the first-line treatment of advanced breast cancer: overall survival analysis from the phase II first study;Ellis;J Clin Oncol,2015

4. 3rd ESO–ESMO international consensus guidelines for advanced breast cancer (ABC 3);Cardoso;Ann Oncol,2017

5. Endocrine therapy for hormone receptor-positive metastatic breast cancer: American society of clinical oncology guideline;Rugo;J Clin Oncol,2016

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Adjuvant and neoadjuvant therapy with or without CDK4/6 inhibitors in HR+/HER2- early breast cancer: a systematic review and meta-analysis;Frontiers in Pharmacology;2024-09-12

2. Unravelling the therapeutic potential of forkhead box proteins in breast cancer: An update (Review);ONCOL REP;2024

3. The adverse events of CDK4/6 inhibitors for HR+/ HER2- breast cancer: an umbrella review of meta-analyses of randomized controlled trials;Frontiers in Pharmacology;2024-01-15

4. Targeting the oncogenic transcription factor FOXM1 to improve outcomes in all subtypes of breast cancer;Breast Cancer Research;2023-06-27

5. Prevalence and Impact Factors of COVID-19 Vaccination Hesitancy Among Breast Cancer Survivors: A Multicenter Cross-Sectional Study in China;Frontiers in Medicine;2021-11-03